Recently, an international group of pediatric rheumatologists and nephrologists met and created a consensus on a standard for a steroid-dosing regimen to treat childhood-onset systemic lupus erythematosus with proliferative lupus…
Sparsentan is a dual endothelin angiotensin receptor antagonist (DEARA) currently being developed for the treatment of IgA nephropathy (IgAN). The newest update on sparsentan was recently shared by Travere Therapeutics via…
A recent study published in Advances in Rheumatology has uncovered 2 potential biomarkers which could be used to predict which lupus nephritis (LN) patients are at the highest risk of severe renal…
The FDA has recently granted Accelerated Approval to Tarpeyo, also called budesonide, to reduce proteinuria in patients with IgA nephropathy (IgAN). Tarpeyo is the first and currently the only treatment…
According to DocWireNews, on December 16, 2021, the U.S. Food and Drug Administration (FDA) granted Accelerated Approval to Tarpeyo (budesonide) delayed-release capsules. The therapy is designed to treat adult…
Dr. Bakris, Dr. Agarwal, Dr. Wright, and Dr. Minkoff have recently come together to discuss how they assess kidney function and ultimately diagnose chronic kidney disease (CKD). Assessing Disease Severity…
In 2020, COVID-19, a novel coronavirus, began impacting the globe. Caused by the SARS-CoV-2 virus, COVID-19 has resulted in 172 million diagnoses and 3.7 million deaths worldwide. While acute kidney…
According to a story from Renal and Neurology News, a recent study has revealed that lupus nephritis, a rare kidney disease associated with lupus, can suddenly recur even years after…
According to a story from the Knowridge Science Report, a recent study conducted by the Japanese Kumamoto University indicates that a therapy commonly used to treat diabetes, called metformin, can…
Immunoglobulin A nephropathy (IgAN) is a glomerular disease which can lead to kidney failure. Between 70 and 100 percent of all IgAN patients also are diagnosed with microscopic hematuria, but…
According to a story from pharmalive.com, the drug company Calliditas Therapeutics will plan to seek approval for its therapy Nefecon from the US Food and Drug Administration (FDA). This approval…
According to a story from BioSpace, a recent study conducted by the biotechnology company Goldfinch Bio in collaboration with academic partners is highlighting the importance of proteinuria in determining outcomes…
According to a press release, biopharmaceutical company Apellis Pharmaceuticals ("Apellis") recently launched registration programs to explore pegcetacoplan for patients with C3 glomerulopathy (C3G), amyotrophic lateral sclerosis (ALS), and immune…
We are learning more everyday about COVID-19. We know that for most people who contract the disease, recovery will be swift and they will return to normal rather quickly. However,…
There's no misunderstanding this fact: renal-replacement therapy is effective for patients with severe acute kidney injuries (AKI). However, states Kenny Walter in MD Magazine, the efficacy of this treatment can depend…
Lupus nephritis causes kidney inflammation and can often lead to chronic kidney disease (CKD). An issue that medical professionals have faced is predicting the likelihood of individual patients developing CKD.…
According to a story from Physician's Weekly, while measuring the concentration of albumin (albuminuria) is widely considered the standard method for staging and screening for chronic kidney disease, a different…
According to a story from Physician's Weekly, a recent study has concluded that the drug allopurinol is not capable of slowing down the progression of chronic kidney disease. The research,…
This morning, SynAct Pharma AB announced in a press release that they began a Phase II clinical trial to determine the efficacy and safety of AP1189 on treating patients with…
It is crazy to think back to a few months ago and see how much has changed. In March, SARS-CoV-2, which you probably know as COVID-19, was declared a global…
Over 200,000 people in the United States are affected by acute kidney injury (AKI) every year, with an additional 13 million people across the world also experiencing it. Acute kidney…
According to a story from BioSpace, the biopharmaceutical company Retrophin, Inc., recently announced that the first patient has been treated in the company's Phase 3 clinical trial testing sparsentan as…
According to Business Wire, a pharmaceutical company, Aurinia Pharmaceuticals Inc., recently announced that they have enrolled the first lupus nephritis patients in the AURORA 2 extension study. Not only this, but Aurinia…
The biopharmaceutical company Complexa, Inc., has announced that the first patient has been dosed on the Phase 2 clinical trial FIRSTx. FIRSTx is a study of the experimental drug CXA-10…
The phase 3 trial of the drug Inlyta for the treatment of patients with a high risk of recurrent renal cell carcinoma (kidney cancer) following nephrectomy (removal of a kidney)…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
